Antibody ADCC Enhancement via Checkpoint Component Merging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody treatments for cancer, such as rituximab and trastuzumab, often result in low or no therapeutic effect due to limited antibody-dependent cell-mediated cytotoxicity (ADCC) in patients, necessitating a method to enhance ADCC for improved therapeutic outcomes.
Innovation Solution
Administering an immunotherapeutic composition comprising a component of an immune system checkpoint or an immunogenic fragment thereof, in conjunction with an antibody, to augment ADCC effects, thereby increasing the therapeutic benefit for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If an antibody is administered alone for cancer treatment, then the antibody can recognize and bind to target antigens on tumor cells, but the therapeutic effect is limited due to insufficient ADCC activity
Solution Approach 1:
The patent combines an antibody with an immunotherapeutic composition containing checkpoint component or immunogenic fragment to create a synergistic therapeutic effect. The checkpoint component enhances ADCC activity by modulating immune checkpoint pathways, while the antibody provides specific target recognition, together overcoming the limitation of insufficient ADCC when antibody is used alone.
Solution Approach 2:
The invention creates a composite immunotherapeutic system comprising both antibody molecules and checkpoint component/immunogenic fragment. This composite approach integrates two different therapeutic mechanisms (antibody-mediated target binding and checkpoint-mediated immune enhancement) into a single treatment regimen, resulting in augmented ADCC activity and improved therapeutic efficacy.
2Ease of operation
If conventional antibody treatments are used, then the treatment protocol is simple, but the therapeutic benefit is low or nonexistent in many patients
Solution Approach 1:
The patent merges antibody therapy with immunotherapeutic composition containing checkpoint component into a single administration protocol. This combination approach maintains relative operational simplicity while significantly enhancing therapeutic benefit through synergistic mechanisms that augment ADCC activity, addressing the limitation of conventional single-antibody treatments.
3Reliability
If the dosage of antibody is increased to improve therapeutic effect, then more target antigens can be bound, but ADCC activity does not proportionally increase and toxicity may rise
Solution Approach 1:
The invention changes the therapeutic parameter from solely increasing antibody dosage to including immunotherapeutic composition with checkpoint component. This parameter change shifts the mechanism of action from passive target binding to active immune system engagement, enhancing ADCC activity through immune modulation rather than simply increasing antibody concentration, thereby avoiding the limitations of dosage escalation.
Data Source
AI summary
The present invention relates to a method for increasing the therapeutic benefit of an antibody to a subject. The improved benefit is typically mediated by an increase in the antibody-dependent cell-mediated cytotoxicity (ADCC) effect of the antibody. The method comprises (a) administering to said subject an immunotherapeutic composition comprising a component of an immune system checkpoint, or an immunogenic fragment of said component; and (b) also administering said antibody to the subject. The increase in therapeutic benefit to the subject may be in respect of any disease for which the said antibody has a prophylactic or therapeutic effect. The disease may be cancer. The invention also relates to said immunotherapeutic composition and said antibody, and to kits comprising same.